🚨 Moderna swings to profit! The biotech giant reported Q3 revenue of $1.31B (+29% YoY), beating the $885M estimate, and net income of $162M vs a $200M loss a year ago. EPS came in at $0.38 vs an expected loss of $1.10. Moderna also lifted its full-year revenue growth guidance to 15-25%, up from up to 10%, on strong international COVID vaccine demand. Shares jumped ~10% in premarket trading. #Moderna #MRNA #Earnings #Biotech #Stocks #StockMarket #Investing #Zimbuck